Please assess the completion status of the following clinical trial:

Trial Title: Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Men with a history of at least one male sexual partner~  * Men is defined as those documented male at birth (including male-to-female transgendered persons)~* HIV-1 infection as documented by any federally approved, licensed HIV test performed in conjunction with screening (ELISA, western blot, or other approved test)~  * Alternatively, this documentation may include a record that another physician has documented that the patient has HIV based on prior ELISA and western blot, or other approved diagnostic tests~* Meets one of the following sets of criteria:~  * Patients receiving antiretroviral therapy:~    * Receipt of antiretroviral therapy for at least 3 months prior to entry~   * No change in antiretroviral therapy within 30 days prior to entry~ * Patients not receiving antiretroviral therapy:~    * CD4-cell count ≥ 350 cells/mm³ within 90 days prior to study entry~   * No plans to start antiretroviral therapy prior to Week 28~* Normal anal cytological result, LSIL/condyloma, or ASCUS result within 90 days prior to entry, and no HGAIN on biopsy~  * No current or history of anal or peri-anal carcinoma~ * No anal cytological result of HSIL, atypical squamous cells suggestive of HSIL (ASC-H), or suggestive of invasive carcinoma at screening; or history of these results~* No presence of penile or scrotal condyloma, LGAIN (condyloma or AIN 1), HGAIN (e.g., AIN 2 or 3, or perianal intraepithelial neoplasia grade 2 or 3), or invasive carcinoma at pre-entry on biopsy~* No history of HGAIN~PATIENT CHARACTERISTICS:~* Karnofsky performance score ≥ 70 within 45 days prior to entry~* Absolute neutrophil count (ANC) \> 750 cells/mm\^3~* Hemoglobin ≥ 9.0 g/dL~* Platelet count ≥ 100,000/mm\^3~* AST (SGOT), ALT (SGPT) ≤ 3 times upper limit of normal (ULN)~* Total or conjugated (direct) bilirubin ≤ 2.5 times ULN within 45 days before study entry, with the exception of isolated hyperbilirubinemia that is considered due to atazanavir~* Calculated creatinine clearance ≥ 60 mL/min~* No hemophilia~* No active drug or alcohol use or dependence that, in the opinion of the site Investigator, would interfere with adherence to study requirements~* No serious illness requiring systemic treatment and/or hospitalization within 45 days prior to entry~* No serious medical or psychiatric illness that, in the opinion of the site Investigator, will interfere with the ability of the subject to give informed consent or adhere to the protocol~* No allergy to yeast or any of the components of Gardasil~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* No prior splenectomy~* No prior receipt of Gardasil or other HPV vaccine~* No use of any systemic antineoplastic or immunomodulatory treatment, systemic corticosteroids for greater than 14 days, investigational vaccines, interleukins, interferons, growth factors, or IVIG within 45 days prior to study entry~* No expected use of any systemic antineoplastic or immunomodulatory treatment, systemic corticosteroids used for greater than 14 days, investigational vaccines, interleukins, interferons, growth factors, or IVIG during study followup~  * No patients with hepatitis C who expect to initiate treatment for hepatitis C (e.g., interferons) during this trial~* Not currently receiving anticoagulation therapy other than acetylsalicylic acid

- Gender: MALE
- Minimum Age: 13 Years
- Maximum Age: 26 Years
- Healthy Volunteers: f

Study Arms:
- Vaccination (Type: EXPERIMENTAL): Gardasil (quadrivalent HPV types 6, 11, 16, 18) vaccination at weeks 0, 8, 24.

Based on this trial design, predict the completion outcome and termination type (if applicable).